IN10018 Plus Nab-Paclitaxel and Cadonilimab for Metastatic, Recurrent, or Persistent Gastric-Type Adenocarcinoma of the Cervix: a Multicenter, Single-Arm, Phase II Trial
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Cadonilimab (Primary) ; Ifebemtinib (Primary) ; Paclitaxel (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 28 Oct 2024 New trial record